TY  - CHAP
M1  - Book, Section
TI  - Antiplatelet Therapies in Contemporary Percutaneous Coronary Intervention
A1  - Jayasuriya, Sasanka
A1  - Pfau, Steven
A2  - Samady, Habib
A2  - Fearon, William F.
A2  - Yeung, Alan C.
A2  - King III, Spencer B.
Y1  - 2017
N1  - 
T2  - Interventional Cardiology, 2e
AB  - In  1979,  Andreas  Gruentzig  reported  his  experience  with  the  first  50  coronary  angioplasty  procedures.  In  those  first  50  patients,  antiplatelet  therapy  was  empiric  and  consisted  of  1.0  g  of  aspirin  (approximately  65  mg)  for  3  days  and  dextran  during  the  procedure.  In  the  36  years  since  that  publication,  the  scientific  understanding  of  arterial  thrombus  formation  in  response  to  arterial  injury  and  clinical  experience  with  pharmacologic  means  to  mitigate  this  process  have  grown  by  immeasurable  proportions.  Specifically,  the  understanding  of  surface  receptors  and  ligands  necessary  for  the  transformation  of  platelets  to  their  active  state,  as  well  as  the  surface  proteins  responsible  for  adherence  to  fibrin,  leukocytes,  and  other  platelets,  has  facilitated  the  development  of  therapies  targeted  to  specific  steps  in  the  activation  sequence.  Clinical  investigation  and  experience  continually  refine  the  circumstances  under  which  specific  therapies  are  best  applied  in  order  to  maximize  benefit  and  minimize  risk.  In  contemporary  coronary  angioplasty,  the  interplay  between  arterial  wall,  platelets,  plaque  components,  clinical  presentation,  stent  design,  stent  components,  and  concomitant  medications  has  resulted  in  a  complex  and  fluid  therapeutic  algorithm  for  antiplatelet  therapy  before,  during,  and  after  percutaneous  coronary  interventions.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesscardiology.mhmedical.com/content.aspx?aid=1146596535
ER  -